Stada-Mabxience Bevacizumab Is Latest To Receive EU Nod

As Riemser’s Thiotepa And Teva Inhalers Also Endorsed By CHMP

Stada and Mabxience have received an endorsement from the EMA for their partnered bevacizumab biosimilar rival to Avastin. Meanwhile, Riemser’s thiotepa generic and two Teva inhalers have also received positive opinions from the CHMP.

Europe
The EMA’s CHMP has recommended several products for approval in Europe • Source: Shutterstock

Further biosimilar competition to Avastin (bevacizumab) is looming in Europe after Stada and Mabxience received positive opinions recommending granting pan-European marketing authorizations for their partnered biosimilar from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Having partnered on the development of biosimilar bevacizumab, Stada and Mabxience received simultaneous positive opinions for their respective Oyavas and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By 

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By 

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By 

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”